JPH11512107A5 - - Google Patents

Info

Publication number
JPH11512107A5
JPH11512107A5 JP1997510839A JP51083997A JPH11512107A5 JP H11512107 A5 JPH11512107 A5 JP H11512107A5 JP 1997510839 A JP1997510839 A JP 1997510839A JP 51083997 A JP51083997 A JP 51083997A JP H11512107 A5 JPH11512107 A5 JP H11512107A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997510839A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11512107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1996/003814 external-priority patent/WO1997009048A1/en
Publication of JPH11512107A publication Critical patent/JPH11512107A/ja
Publication of JPH11512107A5 publication Critical patent/JPH11512107A5/ja
Ceased legal-status Critical Current

Links

JP9510839A 1995-09-09 1996-08-30 チエノトリアゾロジアゼピンのアポリポタンパク質a−iレベル増加のための用途 Ceased JPH11512107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95114163.9 1995-09-09
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (2)

Publication Number Publication Date
JPH11512107A JPH11512107A (ja) 1999-10-19
JPH11512107A5 true JPH11512107A5 (2) 2004-08-12

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9510839A Ceased JPH11512107A (ja) 1995-09-09 1996-08-30 チエノトリアゾロジアゼピンのアポリポタンパク質a−iレベル増加のための用途

Country Status (14)

Country Link
US (1) US5854238A (2)
EP (1) EP0853480B1 (2)
JP (1) JPH11512107A (2)
KR (1) KR19990044460A (2)
CN (1) CN1101680C (2)
AT (1) ATE230600T1 (2)
AU (1) AU725249B2 (2)
BR (1) BR9610390A (2)
CA (1) CA2230477A1 (2)
DE (1) DE69625696T2 (2)
DK (1) DK0853480T3 (2)
ES (1) ES2188783T3 (2)
TR (1) TR199800406T1 (2)
WO (1) WO1997009048A1 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7579319B2 (en) 2004-12-06 2009-08-25 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EA018620B1 (ru) * 2008-10-30 2013-09-30 Сёркомед Ллк ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
MX384074B (es) 2010-05-14 2025-03-12 Dana Farber Cancer Inst Inc Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
JP5913292B2 (ja) * 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 代謝を調節する組成物および方法
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
EP3066101B1 (en) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
KR20160130778A (ko) 2014-02-28 2016-11-14 텐샤 세러퓨틱스 인코포레이티드 고인슐린혈증과 관련된 질환의 치료
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
AU2015339511B2 (en) 2014-10-27 2020-05-14 Tensha Therapeutics, Inc. Bromodomain inhibitors
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
PE20181287A1 (es) 2015-09-11 2018-08-07 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
UA123946C2 (uk) 2015-09-11 2021-06-30 Дана-Фарбер Кенсер Інстітьют, Інк. Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
CA3003288A1 (en) 2015-11-25 2017-06-01 Dana-Farber Cancer Institute, Inc. Bivalent bromodomain inhibitors and uses thereof
MX2020013608A (es) 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
JPS50100096A (2) * 1974-01-08 1975-08-08

Similar Documents

Publication Publication Date Title
JP2000500228A5 (2)
JP2000500033A5 (2)
JP2000500445A5 (2)
JP2000500440A5 (2)
JP2000500327A5 (2)
JPH11501590A5 (2)
JP2000500155A5 (2)
JP2000500406A5 (2)
JP2000500361A5 (2)
JP2000500115A5 (2)
JP2000500322A5 (2)
JP2000500258A5 (2)
JP2000500342A5 (2)
JPH11510414A5 (2)
JP2000500112A5 (2)
JP2000500051A5 (2)
JP2000500166A5 (2)
JP2000500407A5 (2)
JP2000500397A5 (2)
JP2000500019A5 (2)
JP2000500044A5 (2)
JP2000500346A5 (2)
JP2000500090A5 (2)
JP2000500257A5 (2)
JP2000500429A5 (2)